Trials / Completed
CompletedNCT03556345
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2
A Multicenter, Open Label，Single Arm，Phase II Study to Evaluate the Effect and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection in HER2 Overexpressing Local Advanced or Metastatic Gastric Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 127 (actual)
- Sponsor
- RemeGen Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of intravenous RC48-ADC in local advanced or metastatic gastric patients with the overexpression of HER2.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RC48-ADC | 2.5 mg/kg IV every 2 weeks |
Timeline
- Start date
- 2018-07-10
- Primary completion
- 2020-06-01
- Completion
- 2020-08-31
- First posted
- 2018-06-14
- Last updated
- 2022-01-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03556345. Inclusion in this directory is not an endorsement.